Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence

NCT00269750 is registered in ClinicalTrials.gov with Alza Corporation, DE, USA as lead sponsor.

NCT NCT00269750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00269750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence
Lead sponsor
Alza Corporation, DE, USA
Phase
Phase 3
Overall status
Completed
Start date
July 31, 1996
Completion date
February 28, 1997
Enrollment
100
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urge incontinence